Home
News
默认头像

Ascendis Pharma Says FDA Accepts Resubmitted NDA For TransCon PTH In Adults With Hypoparathyroidism

2024-06-07MyfxbookMyfxbook
Ascendis Pharma A/S (ASND) announced Monday that the U.S. Food & Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the
Ascendis Pharma Says FDA Accepts Resubmitted NDA For TransCon PTH In Adults With Hypoparathyroidism

(RTTNews) - Ascendis Pharma A/S (ASND) announced Monday that the U.S. Food & Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism.

The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act (PDUFA) goal date of May 14, 2024.

In the United States, TransCon PTH (palopegteriparatide) is an investigational prodrug of parathyroid hormone (PTH [1-34]) for adult patients with hypoparathyroidism.

Disclaimers

The article is sourced from Myfxbook with the original source credited. The views expressed herein are not affiliated with FXOR; readers are encouraged to approach the content rationally. Copyright belongs to the original author. If unintentional infringement upon media or personal intellectual property rights has occurred, please contact us, and we will promptly remove the content. FXOR merely provides information storage services. The article is compiled and released by FXOR; reprints must indicate the original source.

Myfxbook Enter the brand column

Hottest

About 1 Year Ago

European stocks closed lower on Thursday on concerns the Federal Reserve might not reduce interest rates more than one time this year despite soft consumer price and producer price inflation data.

About 1 Year Ago

John Wiley & Sons, Inc. (WLY) reported Thursday net income for the first quarter of $25.27 million or $0.46 per share, sharply lower than $68.34 million or $1.22 per share in the prior-year quarter.

About 1 Year Ago

Asian stocks rose broadly on Thursday as soft U.S. inflation data helped keep the door open for a Federal Reserve rate cut in September.

About 1 Year Ago

While announcing its widely expected decision to leave interest rates unchanged on Wednesday, the Federal Reserve also revealed officials now expect only one interest rate cut this year. In support of its goals of

About 1 Year Ago

Asian stocks drifted lower on Wednesday as investors awaited key U.S. inflation data as well as a Federal Reserve policy decision later in the day for additional clues on the outlook for interest rates.

home

Home

home

Brokers

home

News

home

Expo

home

Mine